Polycystic ovary syndrome (PCOS) involves hyperandrogenism, insulin resistance, dysregulated LH pulsatility, chronic low-grade inflammation, and disrupted folliculogenesis. It is the most common endocrine disorder in reproductive-age women and has significant metabolic as well as reproductive consequences. Peptide research targets the insulin resistance, hormonal axis dysregulation, and inflammation driving PCOS.
1. Semaglutide — Insulin Resistance / Weight / Androgen Reduction
Insulin resistance is central to PCOS — hyperinsulinemia directly stimulates ovarian androgen production and disrupts GnRH pulsatility. Semaglutide addresses PCOS through multiple mechanisms: reducing insulin levels, promoting significant weight loss (which reduces androgen conversion in fat tissue), and improving menstrual regularity in insulin-resistant PCOS.
Dosing Protocol: 0.25 mg SubQ once weekly. Titrate by 0.25 mg every 4 weeks to effective dose (typically 0.5–1 mg/week for PCOS in lean patients, higher in obese PCOS).
2. Kisspeptin — LH Pulsatility Restoration
PCOS involves dysregulated GnRH/LH pulsatility — abnormally high LH pulse frequency drives excess androgen production. Kisspeptin modulates hypothalamic GnRH secretion and can normalize the aberrant LH pulsatility characteristic of PCOS, restoring normal FSH/LH balance and supporting follicle maturation.
Dosing Protocol: 50–100 mcg SubQ 2–3x weekly. Timing relative to menstrual cycle may optimize effects on folliculogenesis.
3. BPC-157 — Anti-Inflammatory / Ovarian Protection
Chronic low-grade inflammation is both a cause and consequence of PCOS. BPC-157 reduces the systemic inflammatory cytokines that impair insulin signaling and ovarian function, repairs the gut barrier driving metabolic endotoxemia, and has shown protective effects on ovarian tissue in preclinical models.
Dosing Protocol: 250–500 mcg SubQ daily, or 500 mcg oral (arginate) for gut-metabolic axis support. Cycle: 8–12 weeks.
4. Ipamorelin + CJC-1295 — GH/IGF-1 Balance
GH and IGF-1 play important roles in follicle development and ovarian function. In PCOS, GH pulsatility is often disrupted. Ipamorelin/CJC restores physiological GH secretion, improving body composition, insulin sensitivity, and the GH-IGF-1 balance that influences ovarian follicle development.
Dosing Protocol: 200–300 mcg Ipamorelin + 100–200 mcg CJC-1295 SubQ before bed. 5 on/2 off. Cycle: 12 weeks.
Semaglutide addresses the insulin resistance that is the central metabolic driver of PCOS — reducing hyperinsulinemia, androgen excess, and weight simultaneously. Kisspeptin normalizes the dysregulated LH pulsatility that drives androgen overproduction. BPC-157 suppresses the chronic inflammation perpetuating the metabolic dysfunction. Ipamorelin/CJC optimizes the GH/IGF-1 axis that influences both metabolic health and ovarian function.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).